1.

Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis. Ohashi K, Sato A, Takada T, Arai T, Kasahara Y, Hojo M, Nei T, Nakayama H, Motoi N, Urano S, Eda R, Yokoba M, Tsuchihashi Y, Nasuhara Y, Ishii H, Ebina M, Yamaguchi E, Inoue Y, Nakata K, Tazawa R. Eur Respir J. 2012 Mar;39(3):777-80. No abstract available.

2.

IgM-type GM-CSF Autoantibody is Etiologically a Bystander but Associated with IgG-type Autoantibody Production in Autoimmune Pulmonary Alveolar Proteinosis. Nei T, Urano S, Motoi N, Takizawa J, Kaneko C, Kanazawa H, Tazawa R, Nakagaki K, Akagawa KS, Akasaka K, Ichiwata T, Azuma A, Nakata K. Am J Physiol Lung Cell Mol Physiol. 2012 Feb 24. [Epub ahead of print]

3.

Clinical significance of serum lipids in idiopathic pulmonary alveolar proteinosis. Fang CS, Wang YC, Zhang TH, Wu J, Wang W, Wang C, Zhang MY. Lipids Health Dis. 2012 Jan 17;11:12. Free PMC Article

4.

Indium Lung Disease. Cummings KJ, Nakano M, Omae K, Takeuchi K, Chonan T, Xiao YL, Harley RA, Roggli VL, Hebisawa A, Tallaksen RJ, Trapnell BC, Day GA, Saito R, Stanton ML, Suarthana E, Kreiss K. Chest. 2011 Dec 29. [Epub ahead of print] 5.

Direct evidence that GM-CSF inhalation improves lung clearance in pulmonary alveolar proteinosis. Ohashi K, Sato A, Takada T, Arai T, Nei T, Kasahara Y, Motoi N, Hojo M, Urano S, Ishii H, Yokoba M, Eda R, Nakayama H, Nasuhara Y, Tsuchihashi Y, Kaneko C, Kanazawa H, Ebina M, Yamaguchi E, Kirchner J, Inoue Y, Nakata K, Tazawa R. Respir Med. 2012 Feb;106(2):284-93. Epub 2011 Nov 22.

6.

Lentivirus-ABCG1 instillation reduces lipid accumulation and improves lung compliance in GM-CSF knock-out mice. Malur A, Huizar I, Wells G, Barna BP, Malur AG, Thomassen MJ. Biochem Biophys Res Commun. 2011 Nov 18;415(2):288-93. Epub 2011 Oct 18.

7.

Effectiveness of GM-CSF Therapy in Autoimmune Pulmonary Alveolar Proteinosis: A Meta-analysis of Observational Studies. Khan A, Agarwal R, Aggarwal AN. Chest. 2011 Oct 20. [Epub ahead of print]

8.

Indium-tin oxide does not induce GM-CSF autoantibodies. Masuko H, Hizawa N, Chonan T, Amata A, Omae K, Nakano M, Nakata K, Hebisawa A. Am J Respir Crit Care Med. 2011 Sep 15;184(6):741; author reply 741-2. No abstract available.

9.

Pulmonary alveolar proteinosis: new insights from a single-center cohort of 70 patients. Bonella F, Bauer PC, Griese M, Ohshimo S, Guzman J, Costabel U. Respir Med. 2011 Dec;105(12):1908-16. Epub 2011 Sep 6.

10.

Long-term follow-up and treatment of congenital alveolar proteinosis. Griese M, Ripper J, Sibbersen A, Lohse P, Lohse P, Brasch F, Schams A, Pamir A, Schaub B, Muensterer OJ, Schön C, Glöckner-Pagel J, Nicolai T, Reiter K, Hector A. BMC Pediatr. 2011 Aug 17;11:72. Free PMC Article

11.

Elemental analysis of lung tissue particles and intracellular iron content of alveolar macrophages in pulmonary alveolar proteinosis. Shimizu Y, Matsuzaki S, Dobashi K, Yanagitani N, Satoh T, Koka M, Yokoyama A, Ohkubo T, Ishii Y, Kamiya T, Mori M. Respir Res. 2011 Jun 30;12:88. Free PMC Article

12.

Pulmonary alveolar proteinosis. Borie R, Danel C, Debray MP, Taille C, Dombret MC, Aubier M, Epaud R, Crestani B. Eur Respir Rev. 2011 Jun;20(120):98-107. Review.

13.

Pulmonary alveolar proteinosis: Quantitative CT and pulmonary functional correlations. Guan Y, Zeng Q, Yang H, Zheng J, Li S, Gao Y, Deng Y, Mei J, He J, Zhong N. Eur J Radiol. 2011 May 26. [Epub ahead of print]

14.

Relationship between diffuse pulmonary fibrosis, alveolar proteinosis, and granulocytemacrophage colony stimulating factor autoantibodies. Luisetti M, Bruno P, Kadija Z, Suzuki T, Raffa S, Torrisi MR, Campo I, Mariani F, Pozzi E, Trapnell BC, Mariotta S. Respir Care. 2011 Oct;56(10):1608-10. Epub 2011 Apr 19.

15.

An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Kavuru MS, Malur A, Marshall I, Barna BP, Meziane M, Huizar I, Dalrymple H, Karnekar R, Thomassen MJ. Eur Respir J. 2011 Dec;38(6):1361-7. Epub 2011 Apr 8.

16.

Clinical features of secondary pulmonary alveolar proteinosis: pre-mortem cases in Japan. Ishii H, Tazawa R, Kaneko C, Saraya T, Inoue Y, Hamano E, Kogure Y, Tomii K, Terada M, Takada T, Hojo M, Nishida A, Ichiwata T, Trapnell BC, Goto H, Nakata K. Eur Respir J. 2011 Feb;37(2):465-8. No abstract available.

17.

Hereditary pulmonary alveolar proteinosis caused by recessive CSF2RB mutations. Suzuki T, Maranda B, Sakagami T, Catellier P, Couture CY, Carey BC, Chalk C, Trapnell BC. Eur Respir J. 2011 Jan;37(1):201-4. No abstract available. 18.

Whole-lung lavage in infants and children with pulmonary alveolar proteinosis. Reiter K, Schoen C, Griese M, Nicolai T. Paediatr Anaesth. 2010 Dec;20(12):1118-23. doi: 10.1111/j.1460-9592.2010.03442.x.

19.

Adult-onset hereditary pulmonary alveolar proteinosis caused by a single-base deletion in CSF2RB. Tanaka T, Motoi N, Tsuchihashi Y, Tazawa R, Kaneko C, Nei T, Yamamoto T, Hayashi T, Tagawa T, Nagayasu T, Kuribayashi F, Ariyoshi K, Nakata K, Morimoto K. J Med Genet. 2011 Mar;48(3):205-9. Epub 2010 Nov 12.

20.

In Lysinuric Protein Intolerance system y+L activity is defective in monocytes and in GMCSF-differentiated macrophages. Barilli A, Rotoli BM, Visigalli R, Bussolati O, Gazzola GC, Kadija Z, Rodi G, Mariani F, Ruzza ML, Luisetti M, Dall'Asta V. Orphanet J Rare Dis. 2010 Nov 26;5:32. Free PMC Article

21.

Therapeutic whole lung lavage for inhaled plutonium oxide revisited. Morgan C, Bingham D, Holt DC, Jones DM, Lewis NJ. J Radiol Prot. 2010 Dec;30(4):735-46. Epub 2010 Dec 8. Review.

22.

Pulmonary alveolar proteinosis associated with Epstein-Barr virus infection. Edwards C, Primhak R, Cohen MC. Eur Respir J. 2010 Nov;36(5):1214-6. No abstract available.

23.

Pulmonary alveolar proteinosis in workers at an indium processing facility. Lison D, Delos M. Am J Respir Crit Care Med. 2010 Aug 15;182(4):578; author reply 578-9. No abstract available. Free Article

24.

Therapy options in pulmonary alveolar proteinosis. Luisetti M, Kadija Z, Mariani F, Rodi G, Campo I, Trapnell BC. Ther Adv Respir Dis. 2010 Aug;4(4):239-48. Epub 2010 Jul 20. Review.

25.

Immune dysregulation in the pathogenesis of pulmonary alveolar proteinosis. Martinez-Moczygemba M, Huston DP. Curr Allergy Asthma Rep. 2010 Sep;10(5):320-5. Review.

26.

The molecular basis of pulmonary alveolar proteinosis. Carey B, Trapnell BC. Clin Immunol. 2010 May;135(2):223-35. Epub 2010 Mar 25. Review. Free PMC Article

27.

Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. Sakagami T, Beck D, Uchida K, Suzuki T, Carey BC, Nakata K, Keller G, Wood RE, Wert SE, Ikegami M, Whitsett JA, Luisetti M, Davies S, Krischer JP, Brody A, Ryckman F, Trapnell BC. Am J Respir Crit Care Med. 2010 Jul 1;182(1):49-61. Epub 2010 Mar 11. Free PMC Article

28.

Pulmonary alveolar proteinosis versus exogenous lipoid pneumonia showing crazy-paving pattern: Comparison of their clinical features and high-resolution CT findings. Choi HK, Park CM, Goo JM, Lee HJ. Acta Radiol. 2010 May;51(4):407-12. 29.

Clinical features and outcomes of idiopathic pulmonary alveolar proteinosis in Korean population. Byun MK, Kim DS, Kim YW, Chung MP, Shim JJ, Cha SI, Uh ST, Park CS, Jeong SH, Park YB, Lee HL, Park MS. J Korean Med Sci. 2010 Mar;25(3):393-8. Epub 2010 Feb 17. Free PMC Article

30.

Pulmonary alveolar proteinosis associated with dust inhalation: not secondary but autoimmune? Costabel U, Nakata K. Am J Respir Crit Care Med. 2010 Mar 1;181(5):427-8. No abstract available. Free Article

31.

Targeted PPAR{gamma} deficiency in alveolar macrophages disrupts surfactant catabolism. Baker AD, Malur A, Barna BP, Ghosh S, Kavuru MS, Malur AG, Thomassen MJ. J Lipid Res. 2010 Jun;51(6):1325-31. Epub 2010 Jan 11. Free PMC Article

32.

Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. Sakagami T, Uchida K, Suzuki T, Carey BC, Wood RE, Wert SE, Whitsett JA, Trapnell BC, Luisetti M. N Engl J Med. 2009 Dec 31;361(27):2679-81. No abstract available. Free Article

33.

Pulmonary alveolar proteinosis in workers at an indium processing facility. Cummings KJ, Donat WE, Ettensohn DB, Roggli VL, Ingram P, Kreiss K. Am J Respir Crit Care Med. 2010 Mar 1;181(5):458-64. Epub 2009 Dec 17. Free PMC Article

34.

Respiratory disease in Niemann-Pick type C2 is caused by pulmonary alveolar proteinosis. Griese M, Brasch F, Aldana VR, Cabrera MM, Goelnitz U, Ikonen E, Karam BJ, Liebisch G, Linder MD, Lohse P, Meyer W, Schmitz G, Pamir A, Ripper J, Rolfs A, Schams A, Lezana FJ. Clin Genet. 2010 Feb;77(2):119-30. Epub 2009 Dec 10.

35.

Whole-lung lavage for pulmonary alveolar proteinosis. Michaud G, Reddy C, Ernst A. Chest. 2009 Dec;136(6):1678-81. Free Article

36.

Pulmonary alveolar proteinosis, a primary immunodeficiency of impaired GM-CSF stimulation of macrophages. Trapnell BC, Carey BC, Uchida K, Suzuki T. Curr Opin Immunol. 2009 Oct;21(5):514-21. Epub 2009 Sep 30. Review. Free PMC Article

37.

Pulmonary alveolar proteinosis: a bench-to-bedside story of granulocyte-macrophage colony-stimulating factor dysfunction. Greenhill SR, Kotton DN. Chest. 2009 Aug;136(2):571-7. Review. Free Article

38.

Alveolar proteinosis syndrome: pathogenesis, diagnosis, and management. Huizar I, Kavuru MS. Curr Opin Pulm Med. 2009 Sep;15(5):491-8. Review.

39.

Pulmonary alveolar proteinosis in China: a systematic review of 241 cases. Xu Z, Jing J, Wang H, Xu F, Wang J. Respirology. 2009 Jul;14(5):761-6. Epub 2009 May 19. Review.

40.

Rituximab therapy in autoimmune pulmonary alveolar proteinosis. Borie R, Debray MP, Laine C, Aubier M, Crestani B. Eur Respir J. 2009 Jun;33(6):1503-6.

41.

Plasmapheresis for treatment of pulmonary alveolar proteinosis. Luisetti M, Rodi G, Perotti C, Campo I, Mariani F, Pozzi E, Trapnell BC. Eur Respir J. 2009 May;33(5):1220-2. Free Article

42.

Clinical importance of bronchoalveolar lavage fluid and blood cytokines, surfactant protein D, and Kerbs von Lungren 6 antigen in idiopathic pulmonary alveolar proteinosis. Lin FC, Chen YC, Chang SC. Mayo Clin Proc. 2008 Dec;83(12):1344-9.

43.

Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. Suzuki T, Sakagami T, Rubin BK, Nogee LM, Wood RE, Zimmerman SL, Smolarek T, Dishop MK, Wert SE, Whitsett JA, Grabowski G, Carey BC, Stevens C, van der Loo JC, Trapnell BC. J Exp Med. 2008 Nov 24;205(12):2703-10. Epub 2008 Oct 27. Free PMC Article

44.

Peroxisome proliferator-activated receptor-gamma regulates the expression of alveolar macrophage macrophage colony-stimulating factor. Bonfield TL, Thomassen MJ, Farver CF, Abraham S, Koloze MT, Zhang X, Mosser DM, Culver DA. J Immunol. 2008 Jul 1;181(1):235-42. Free PMC Article

45.

Immunohistochemical localisation of surfactant proteins A and D, and KL-6 in pulmonary alveolar proteinosis. Ohtsuki Y, Kobayashi M, Yoshida S, Kishimoto N, Kubo K, Yokoyama A, Lee GH, Furihata M. Pathology. 2008 Aug;40(5):536-9. No abstract available.

46.

A combination therapy of whole lung lavage and GM-CSF inhalation in pulmonary alveolar proteinosis. Yamamoto H, Yamaguchi E, Agata H, Kandatsu N, Komatsu T, Kawai S, Baba K, Awaya T, Nishikomori R, Tsurusawa M, Nakata K. Pediatr Pulmonol. 2008 Aug;43(8):828-30.

47.

Cathepsin H and napsin A are active in the alveoli and increased in alveolar proteinosis. Woischnik M, Bauer A, Aboutaam R, Pamir A, Stanzel F, de Blic J, Griese M. Eur Respir J. 2008 Jun;31(6):1197-204. Epub 2008 Jan 23. Free Article

48.

Differences in the immunolocalization of surfactant protein (SP)-A, SP-D, and KL-6 in pulmonary alveolar proteinosis. Kobayashi M, Takeuchi T, Ohtsuki Y. Pathol Int. 2008 Mar;58(3):203-7.

49.

Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ichiwata T, Tanaka N, Yamaguchi E, Eda R, Oishi K, Tsuchihashi Y, Kaneko C, Nukiwa T, Sakatani M, Krischer JP, Nakata K; Japanese Center of the Rare Lung Diseases Consortium. Am J Respir Crit Care Med. 2008 Apr 1;177(7):752-62. Epub 2008 Jan 17. Free PMC Article

50.

Iron homeostasis and oxidative stress in idiopathic pulmonary alveolar proteinosis: a case-control study. Ghio AJ, Stonehuerner JG, Richards JH, Crissman KM, Roggli VL, Piantadosi CA, Carraway MS. Respir Res. 2008 Jan 23;9:10. Free PMC Article

51.

Lung alveolar proteomics of bronchoalveolar lavage from a pulmonary alveolar proteinosis patient using high-resolution FTICR mass spectrometry. Bai Y, Galetskiy D, Damoc E, Ripper J, Woischnik M, Griese M, Liu Z, Liu S, Przybylski M. Anal Bioanal Chem. 2007 Oct;389(4):1075-85. Epub 2007 Jun 20.

52.

Successful whole lung lavage in pulmonary alveolar proteinosis secondary to lysinuric protein intolerance: a case report. Ceruti M, Rodi G, Stella GM, Adami A, Bolongaro A, Baritussio A, Pozzi E, Luisetti M. Orphanet J Rare Dis. 2007 Mar 26;2:14. Free PMC Article

53.

Pulmonary alveolar proteinosis: a rare pulmonary toxicity of sirolimus. Pedroso SL, Martins LS, Sousa S, Reis A, Dias L, Henriques AC, Sarmento AM, Cabrita A. Transpl Int. 2007 Mar;20(3):291-6.

54.

GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. Uchida K, Beck DC, Yamamoto T, Berclaz PY, Abe S, Staudt MK, Carey BC, Filippi MD, Wert SE, Denson LA, Puchalski JT, Hauck DM, Trapnell BC. N Engl J Med. 2007 Feb 8;356(6):567-79. Free Article

55.

Bilateral whole lung lavage in the treatment of pulmonary alveolar proteinosis. Kumar P, Sengupta S, Rudra A, Maitra G, Ramasubban S, Mukhopadhyay A. Anesth Analg. 2007 Feb;104(2):464-5. No abstract available. Free Article

56.

Pulmonary alveolar proteinosis. Ioachimescu OC, Kavuru MS. Chron Respir Dis. 2006;3(3):149-59. Review.

57.

Serum antibody against granulocyte/macrophage colony-stimulating factor and KL-6 in idiopathic pulmonary alveolar proteinosis. Nara M, Sano K, Ogawa H, Tamada T, Nagaoka M, Okada K, Watanabe M, Moriya T, Miki H, Nakata K, Ichinose M, Hattori T. Tohoku J Exp Med. 2006 Apr;208(4):349-54. Free Article

58.

Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis. Lin FC, Chang GD, Chern MS, Chen YC, Chang SC. Thorax. 2006 Jun;61(6):528-34. Epub 2006 Mar 3. Free PMC Article

59.

Pulmonary alveolar proteinosis: a new autoimmune disease. Costabel U, Guzman J. Sarcoidosis Vasc Diffuse Lung Dis. 2005 Dec;22 Suppl 1:S67-73. Review.

60.

Granulocyte-macrophage colony-stimulating factor inhalation therapy for patients with idiopathic pulmonary alveolar proteinosis: a pilot study; and long-term treatment with aerosolized granulocyte-macrophage colony-stimulating factor: a case report. Tazawa R, Nakata K, Inoue Y, Nukiwa T. Respirology. 2006 Jan;11 Suppl:S61-4.

61.

Therapeutic lung lavages in children and adults. Paschen C, Reiter K, Stanzel F, Teschler H, Griese M. Respir Res. 2005 Nov 22;6:138. Free PMC Article

62.

Elevated gelatinase activity in pulmonary alveolar proteinosis: role of macrophage-colony stimulating factor. Bonfield TL, Swaisgood CM, Barna BP, Farver CF, Kavuru MS, Thomassen MJ. J Leukoc Biol. 2006 Jan;79(1):133-9. Epub 2005 Nov 7.

63.

Protein oxidation by chronic pulmonary diseases in children. Starosta V, Griese M. Pediatr Pulmonol. 2006 Jan;41(1):67-73.

64.

Pulmonary Alveolar Proteinosis: recent advances. Mazzone PJ, Jane Thomassen M, Kavuru MS. Semin Respir Crit Care Med. 2002 Apr;23(2):115-26.

65.

Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Tazawa R, Hamano E, Arai T, Ohta H, Ishimoto O, Uchida K, Watanabe M, Saito J, Takeshita M, Hirabayashi Y, Ishige I, Eishi Y, Hagiwara K, Ebina M, Inoue Y, Nakata K, Nukiwa T. Am J Respir Crit Care Med. 2005 May 15;171(10):1142-9. Epub 2005 Feb 25. Free Article

66.

Anti-GM-CSF antibodies in paediatric pulmonary alveolar proteinosis. Latzin P, Tredano M, Wüst Y, de Blic J, Nicolai T, Bewig B, Stanzel F, Köhler D, Bahuau M, Griese M. Thorax. 2005 Jan;60(1):39-44. Free PMC Article

67.

Serum neutralizing capacity of GM-CSF reflects disease severity in a patient with pulmonary alveolar proteinosis successfully treated with inhaled GM-CSF. Arai T, Hamano E, Inoue Y, Ryushi T, Nukiwa T, Sakatani M, Nakata K. Respir Med. 2004 Dec;98(12):1227-30.

68.

Pulmonary alveolar proteinosis. What is the role of GM-CSF in disease pathogenesis and treatment? Seymour JF, Presneill JJ. Treat Respir Med. 2004;3(4):229-34. Review. No abstract available.

69.

Pulmonary alveolar proteinosis. Clinical manifestations and optimal treatment strategies. Venkateshiah SB, Thomassen MJ, Kavuru MS. Treat Respir Med. 2004;3(4):217-27. Review.

70.

Pulmonary alveolar proteinosis. Presneill JJ, Nakata K, Inoue Y, Seymour JF. Clin Chest Med. 2004 Sep;25(3):593-613, viii. Review.

71.

The benefits of whole lung lavage in pulmonary alveolar proteinosis. Morgan C. Eur Respir J. 2004 Apr;23(4):503-5. No abstract available. Free Article

72.

Pulmonary alveolar proteinosis. Trapnell BC, Whitsett JA, Nakata K. N Engl J Med. 2003 Dec 25;349(26):2527-39. Review. No abstract available.

73.

High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Uchida K, Nakata K, Trapnell BC, Terakawa T, Hamano E, Mikami A, Matsushita I, Seymour JF, Oh-Eda M, Ishige I, Eishi Y, Kitamura T, Yamada Y, Hanaoka K, Keicho N. Blood. 2004 Feb 1;103(3):1089-98. Epub 2003 Sep 25. Free Article

74.

Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis. Seymour JF, Doyle IR, Nakata K, Presneill JJ, Schoch OD, Hamano E, Uchida K, Fisher R, Dunn AR. Thorax. 2003 Mar;58(3):252-7. Free PMC Article

75.

Proteomic analysis of human bronchoalveolar lavage fluid: expression profiling of surfactantassociated protein A isomers derived from human pulmonary alveolar proteinosis using immunoaffinity detection. He C. Proteomics. 2003 Jan;3(1):87-94.

76.

Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Seymour JF, Presneill JJ, Schoch OD, Downie GH, Moore PE, Doyle IR, Vincent JM, Nakata K, Kitamura T, Langton D, Pain MC, Dunn AR. Am J Respir Crit Care Med. 2001 Feb;163(2):524-31. Free Article

77.

Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Kitamura T, Uchida K, Tanaka N, Tsuchiya T, Watanabe J, Yamada Y, Hanaoka K, Seymour JF, Schoch OD, Doyle I, Inoue Y, Sakatani M, Kudoh S, Azuma A, Nukiwa T, Tomita T, Katagiri M, Fujita A, Kurashima A, Kanegasaki S, Nakata K. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):658-62.

78.

Pulmonary alveolar proteinosis is a disease of decreased availability of GM-CSF rather than an intrinsic cellular defect. Thomassen MJ, Yi T, Raychaudhuri B, Malur A, Kavuru MS. Clin Immunol. 2000 May;95(2):85-92.

79.

Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis. Shah PL, Hansell D, Lawson PR, Reid KB, Morgan C. Thorax. 2000 Jan;55(1):67-77. Review. No abstract available. Free PMC Article

80.

Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. Kitamura T, Tanaka N, Watanabe J, Uchida, Kanegasaki S, Yamada Y, Nakata K. J Exp Med. 1999 Sep 20;190(6):875-80. Free PMC Article

81.

Serum KL-6 level as a monitoring marker in a patient with pulmonary alveolar proteinosis. Nakajima M, Manabe T, Niki Y, Matsushima T. Thorax. 1998 Sep;53(9):809-11. Free PMC Article

82.

Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice. Reed JA, Ikegami M, Cianciolo ER, Lu W, Cho PS, Hull W, Jobe AH, Whitsett JA. Am J Physiol. 1999 Apr;276(4 Pt 1):L556-63. Free Article

83.

Pulmonary alveolar proteinosis: clinical features and outcomes. Goldstein LS, Kavuru MS, Curtis-McCarthy P, Christie HA, Farver C, Stoller JK. Chest. 1998 Nov;114(5):1357-62. Free Article

84.

Serum and bronchoalveolar fluid KL-6 levels in patients with pulmonary alveolar proteinosis. Takahashi T, Munakata M, Suzuki I, Kawakami Y. Am J Respir Crit Care Med. 1998 Oct;158(4):1294-8. Free Article

85.

Whole-lung lavage in alveolar proteinosis by a modified lavage technique. Bingisser R, Kaplan V, Zollinger A, Russi EW. Chest. 1998 Jun;113(6):1718-9. Free Article

86.

Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression. Dirksen U, Nishinakamura R, Groneck P, Hattenhorst U, Nogee L, Murray R, Burdach S. J Clin Invest. 1997 Nov 1;100(9):2211-7. Free PMC Article

87.

GM-CSF gene expression is normal but protein release is absent in a patient with pulmonary alveolar proteinosis. Tchou-Wong KM, Harkin TJ, Chi C, Bodkin M, Rom WN. Am J Respir Crit Care Med. 1997 Dec;156(6):1999-2002. Erratum in: Am J Respir Crit Care Med 1998 Apr;157(4 Pt 1):1353. Free Article

88.

Pulmonary alveolar proteinosis: high-resolution CT, chest radiographic, and functional correlations. Lee KN, Levin DL, Webb WR, Chen D, Storto ML, Golden JA. Chest. 1997 Apr;111(4):989-95. Free Article

89.

Bronchoalveolar lavage with trypsin in pulmonary alveolar proteinosis. Nagasaka Y, Takahashi M, Ueshima H, Tohda Y, Nakajima S. Thorax. 1996 Jul;51(7):769-70. Free PMC Article

90.

Pulmonary alveolar proteinosis in SCID mice. Jennings VM, Dillehay DL, Webb SK, Brown LA. Am J Respir Cell Mol Biol. 1995 Sep;13(3):297-306. Free Article

91.

Elevated levels of lung surfactant protein A in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis. Kuroki Y, Tsutahara S, Shijubo N, Takahashi H, Shiratori M, Hattori A, Honda Y, Abe S, Akino T. Am Rev Respir Dis. 1993 Mar;147(3):723-9.

8442609

[PubMed - indexed for MEDLINE]

92.

Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. Nogee LM, de Mello DE, Dehner LP, Colten HR. N Engl J Med. 1993 Feb 11;328(6):406-10. No abstract available. Free Article

93.

Accumulation of surfactant protein D in human pulmonary alveolar proteinosis. Crouch E, Persson A, Chang D. Am J Pathol. 1993 Jan;142(1):241-8. Free PMC Article

94.

Bronchoalveolar lavage cell data in alveolar proteinosis. Milleron BJ, Costabel U, Teschler H, Ziesche R, Cadranel JL, Matthys H, Akoun GM. Am Rev Respir Dis. 1991 Dec;144(6):1330-2.

95.

The clinical role of BAL in alveolar proteinosis. Danel C, Israel-Biet D, Costabel U, Rossi GA, Wallaert B. Eur Respir J. 1990 Sep;3(8):950-1, 961-9. No abstract available.

96.

The clinical and physiological effect of whole-lung lavage in pulmonary alveolar proteinosis: a ten-year experience. Selecky PA, Wasserman K, Benfield JR, Lippmann M. Ann Thorac Surg. 1977 Nov;24(5):451-61.

97.

Bronchopulmonary lavage. New techniques and observations. Ramirez J. Dis Chest. 1966 Dec;50(6):581-8. No abstract available. Free Article

98.

Biological effect of pulmonary washings from cases of alveolar proteinosis. Ramirez J, Savard EV, Hawkins JE. Am Rev Respir Dis. 1966 Aug;94(2):244-6. No abstract available.

99.

Pulmonary alveolar proteinosis: diagnosis and treatment. Ramírez Rivera J. Bol Asoc Med P R. 1966 Feb;58(2):58-64. No abstract available.

100.

Bronchopulmonary lavage in man. Ramirez J, Kieffer RF Jr, Ball WC Jr. Ann Intern Med. 1965 Nov;63(5):819-28. No abstract available.

101.

PULMONARY ALVEOLAR PROTEINOSIS. ENDOBRONCHIAL TREATMENT. RAMIREZ J, CAMPBELL GD. Ann Intern Med. 1965 Sep;63:429-41. No abstract available.

102.

Pulmonary alveolar proteinosis. ROSEN SH, CASTLEMAN B, LIEBOW AA. N Engl J Med. 1958 Jun 5;258(23):1123-42. No abstract available.